Business context and reporting period
This is Pieris Pharmaceuticals, Inc.’s unaudited Form 10-Q for the quarter and six months ended June 30, 2015; the request metadata names a different company. Pieris is a clinical-stage biopharmaceutical company developing Anticalin-based drug candidates. It had no product-sales revenue. Comparisons are with the corresponding 2014 periods.
Financial performance and liquidity
| Metric | Q2 2015 | Q2 2014 | Six months 2015 | Six months 2014 |
|---|---|---|---|---|
| Revenue | $0.160m | $0.698m | $0.378m | $2.071m |
| R&D expense | $1.726m | $1.119m | $3.250m | $2.342m |
| G&A expense | $1.969m | $2.349m | $4.363m | $3.171m |
| Net loss | $3.530m | $2.882m | $7.235m | $3.662m |
| Net loss per share | $0.12 | $0.24 | $0.25 | $0.31 |
At June 30, cash and cash equivalents were $10.027m, versus $18.474m at December 31, 2014. Six-month operating cash use was $6.676m (up from $3.407m); investing cash use was reported as $0.072m and financing cash use was $1.171m. Total assets were $14.478m, current liabilities $3.022m, and total liabilities $3.330m. The TBG bank loan was repaid in full during the first quarter; no bank loan remained at June 30. Accumulated deficit was $73.042m. Operating margins are not meaningful given the company’s development-stage operations and limited collaboration and grant revenue.
Material changes versus prior comparable periods
- Revenue fell sharply as collaboration research projects were handed over to partners in 2014 and related research funding and deferred upfront payments declined. 2015 revenue was primarily European Commission grant reimbursement for PRS-080 activity; no collaboration milestone revenue was recorded in the first half.
- R&D spending rose, mainly due to PRS-080 clinical-trial costs and increased PRS-300 immuno-oncology program activity. Six-month G&A also increased, including public-company, consulting, legal and investor-relations costs and non-cash stock compensation.
- Net loss widened year over year for both the quarter and six-month period, while loss per share decreased, reflecting the much higher weighted-average share count following the 2014 acquisition and financing.
- Foreign-currency translation produced a $0.501m comprehensive loss adjustment for the first half of 2015.
Outlook, commentary, and risks
- Management expected substantial ongoing losses and rising cash needs as programs advance. It stated that June 30 cash was expected to fund operations and capital expenditures for at least 12 months, but also said additional funding would be required to continue planned operations.
- After quarter-end, Pieris completed a public offering of 9,090,909 shares and an over-allotment of 1,211,827 shares at $2.75 per share, for $28.3m gross and approximately $25.8m net proceeds. The company planned to use proceeds for R&D, working capital and general corporate purposes.
- Management reported completion of healthy-volunteer dosing in the PRS-080 Phase I trial, with no dose-limiting toxicities and no maximum tolerated dose reached; results were expected in the second half of 2015. PRS-060 remained preclinical, with a Phase I trial intended for 2017. The company intended to select a 300-Series candidate for IND-enabling preclinical work by year-end 2015. These are plans, not guaranteed outcomes.
- A July 2015 Daiichi Sankyo milestone was triggered by positive in-vivo proof-of-concept data and progression through a non-GLP primate toxicity study; the undisclosed payment was expected in Q3 2015.
- The TUM arbitration concerns out-license fees: Pieris calculated approximately $0.4m due, while TUM asserted approximately $3.4m and filed a counterclaim of €2.529m (reported as $3.061m). An adverse ruling could materially affect results and financial condition; timing of the decision was unknown. The filing gives inconsistent reserve figures: $302,273 in the financial-statement note and $327,937 in the legal-proceedings discussion.
- Disclosure controls and procedures were deemed ineffective due to a previously disclosed material weakness in internal control over financial reporting; no material control changes were reported during the quarter. The company cited clinical, regulatory, financing, intellectual-property, collaboration and third-party execution risks. No material changes to previously disclosed risk factors were reported.
Most important facts to verify
- Confirm the filing identity: the supplied filing is for Pieris Pharmaceuticals, Inc., not the company named in the request metadata.
- Verify the TUM arbitration reserve amount and subsequent decision or settlement status, given the conflicting reserve disclosures.
- Track the timing and outcome of PRS-080 Phase I results, PRS-060 development, and selection and advancement of a 300-Series candidate.
- Confirm receipt and amount of the undisclosed Daiichi Sankyo milestone and assess cash runway against actual R&D spending after the offering.
- Review remediation of the material weakness and progress toward effective disclosure controls.